.Risk predictors to primary endpoint - ICU admission, need for MV and hospital mortality
Tocilizumab (2.6%), convalescent plasma (16.5%), oseltamivir (29.6%) and others antibiotics (79.7%), excluding AZM, were administered as adjunct therapy. Among patients admitted to the ICU, 57.6% (68) received vasopressor and supplemental oxygen without positive pressure was used in 56.9% (254). Positive non-invasive ventilation including HFNC and BiPAP were used in 23.9% (107) while MV in 21.1% (97). HFNC oxygen therapy was able to prevent the patient’s progression to MV in 31.8% of cases.
Overall, 86.7% (398) were discharged alive and 4.5% (21) were still hospitalized by dataset freeze date. Of patients admitted to the ICU, 25.7% (35) died and when MV was required, the mortality increased to 34.0% (33). Among dead patients, the median age was 83.3 years (IQR, 75.5 to 89.5) with the length of stay in hospital of 25.3 (SD±22.5) days, 22.8 (SD±18.7) in ICU and 21.2 (SD±17.3) in MV. The main clinical predictors related to increase the risk for mortality (>70%), were: age >65 years, presence of up one comorbidity, pulmonary involvement ≥50%, saturation <93%, lymphocyte <900mm3, D-dimers >1,250 ng/mL and CRP >8.0 mg/dL at admission, oxygen requirement through BiPAP or HFNC, and ICU admission and MV required during hospitalization were also associated with a higher risk of death (Figure 2) (Table).